Regulations and Norms for Reuse of Residual Clinical Biospecimens and Health Data

2021 ◽  
pp. 019394592110292
Author(s):  
Elizabeth E. Umberfield ◽  
Sharon L. R. Kardia ◽  
Yun Jiang ◽  
Andrea K. Thomer ◽  
Marcelline R. Harris

Nurse scientists are increasingly interested in conducting secondary research using real world collections of biospecimens and health data. The purposes of this scoping review are to (a) identify federal regulations and norms that bear authority or give guidance over reuse of residual clinical biospecimens and health data, (b) summarize domain experts’ interpretations of permissions of such reuse, and (c) summarize key issues for interpreting regulations and norms. Final analysis included 25 manuscripts and 23 regulations and norms. This review illustrates contextual complexity for reusing residual clinical biospecimens and health data, and explores issues such as privacy, confidentiality, and deriving genetic information from biospecimens. Inconsistencies make it difficult to interpret, which regulations or norms apply, or if applicable regulations or norms are congruent. Tools are necessary to support consistent, expert-informed consent processes and downstream reuse of residual clinical biospecimens and health data by nurse scientists.

2022 ◽  
pp. 1-16
Author(s):  
Elizabeth E. Umberfield ◽  
Cooper Stansbury ◽  
Kathleen Ford ◽  
Yun Jiang ◽  
Sharon L.R. Kardia ◽  
...  

The purpose of this study was to evaluate, revise, and extend the Informed Consent Ontology (ICO) for expressing clinical permissions, including reuse of residual clinical biospecimens and health data. This study followed a formative evaluation design and used a bottom-up modeling approach. Data were collected from the literature on US federal regulations and a study of clinical consent forms. Eleven federal regulations and fifteen permission-sentences from clinical consent forms were iteratively modeled to identify entities and their relationships, followed by community reflection and negotiation based on a series of predetermined evaluation questions. ICO included fifty-two classes and twelve object properties necessary when modeling, demonstrating appropriateness of extending ICO for the clinical domain. Twenty-six additional classes were imported into ICO from other ontologies, and twelve new classes were recommended for development. This work addresses a critical gap in formally representing permissions clinical permissions, including reuse of residual clinical biospecimens and health data. It makes missing content available to the OBO Foundry, enabling use alongside other widely-adopted biomedical ontologies. ICO serves as a machine-interpretable and interoperable tool for responsible reuse of residual clinical biospecimens and health data at scale.


2019 ◽  
Vol 9 (2) ◽  
pp. 21-42
Author(s):  
Tengku Adil Tengku Izhar ◽  
Torab Torabi ◽  
M. Ishaq Bhatti

This article proposes the GOAL-Framework for the evaluation of organizational goals based on an ontology. The aim is to capture and analyze relevant data for the organization goals because determining relevant data is a key to delivering value from massive amounts of data for better decision-making in relation to the organizational goals achievement. The framework will allow the domain experts and entrepreneurs to evaluate relevant organizational data to assist the decision-making process with respect to the organizational goals. Hence, they will be able to identify to what extent certain organizational goals could be achieved. In order to test the flexibility and applicability of the GOAL-Framework, a case study is presented to explain how the framework is implemented and applied to a real world situation. The outcome of the case study demonstrates that the framework can be applied for analysis and decision-making based on the metrics using the dashboard to evaluate the extent to which the organizational goals could be achieved.


Author(s):  
Charlotte M Roy ◽  
E Brennan Bollman ◽  
Laura M Carson ◽  
Alexander J Northrop ◽  
Elizabeth F Jackson ◽  
...  

Abstract Background The COVID-19 pandemic and global efforts to contain its spread, such as stay-at-home orders and transportation shutdowns, have created new barriers to accessing healthcare, resulting in changes in service delivery and utilization globally. The purpose of this study is to provide an overview of the literature published thus far on the indirect health effects of COVID-19 and to explore the data sources and methodologies being used to assess indirect health effects. Methods A scoping review of peer-reviewed literature using three search engines was performed. Results One hundred and seventy studies were included in the final analysis. Nearly half (46.5%) of included studies focused on cardiovascular health outcomes. The main methodologies used were observational analytic and surveys. Data were drawn from individual health facilities, multicentre networks, regional registries, and national health information systems. Most studies were conducted in high-income countries with only 35.4% of studies representing low- and middle-income countries (LMICs). Conclusion Healthcare utilization for non-COVID-19 conditions has decreased almost universally, across both high- and lower-income countries. The pandemic’s impact on non-COVID-19 health outcomes, particularly for chronic diseases, may take years to fully manifest and should be a topic of ongoing study. Future research should be tied to system improvement and the promotion of health equity, with researchers identifying potentially actionable findings for national, regional and local health leadership. Public health professionals must also seek to address the disparity in published data from LMICs as compared with high-income countries.


Patterns ◽  
2020 ◽  
pp. 100188
Author(s):  
Allison Shapiro ◽  
Nicole Marinsek ◽  
Ieuan Clay ◽  
Benjamin Bradshaw ◽  
Ernesto Ramirez ◽  
...  
Keyword(s):  

Author(s):  
Patrizia Bisiacchi ◽  
Elisa Cainelli

AbstractAsymmetry characterizes the brain in both structure and function. Anatomical asymmetries explain only a fraction of functional variability in lateralization, with structural and functional asymmetries developing at different periods of life and in different ways. In this work, we perform a scoping review of the cerebral asymmetries in the first brain development phases. We included all English-written studies providing direct evidence of hemispheric asymmetries in full-term neonates, foetuses, and premature infants, both at term post-conception and before. The final analysis included 57 studies. The reviewed literature shows large variability in the used techniques and methodological procedures. Most structural studies investigated the temporal lobe, showing a temporal planum more pronounced on the left than on the right (although not all data agree), a morphological asymmetry already present from the 29th week of gestation. Other brain structures have been poorly investigated, and the results are even more discordant. Unlike data on structural asymmetries, functional data agree with each other, identifying a leftward dominance for speech stimuli and an overall dominance of the right hemisphere in all other functional conditions. This generalized dominance of the right hemisphere for all conditions (except linguistic stimuli) is in line with theories stating that the right hemisphere develops earlier and that its development is less subject to external influences because it sustains functions necessary to survive.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yiqing Zhao ◽  
Saravut J. Weroha ◽  
Ellen L. Goode ◽  
Hongfang Liu ◽  
Chen Wang

Abstract Background Next-generation sequencing provides comprehensive information about individuals’ genetic makeup and is commonplace in oncology clinical practice. However, the utility of genetic information in the clinical decision-making process has not been examined extensively from a real-world, data-driven perspective. Through mining real-world data (RWD) from clinical notes, we could extract patients’ genetic information and further associate treatment decisions with genetic information. Methods We proposed a real-world evidence (RWE) study framework that incorporates context-based natural language processing (NLP) methods and data quality examination before final association analysis. The framework was demonstrated in a Foundation-tested women cancer cohort (N = 196). Upon retrieval of patients’ genetic information using NLP system, we assessed the completeness of genetic data captured in unstructured clinical notes according to a genetic data-model. We examined the distribution of different topics regarding BRCA1/2 throughout patients’ treatment process, and then analyzed the association between BRCA1/2 mutation status and the discussion/prescription of targeted therapy. Results We identified seven topics in the clinical context of genetic mentions including: Information, Evaluation, Insurance, Order, Negative, Positive, and Variants of unknown significance. Our rule-based system achieved a precision of 0.87, recall of 0.93 and F-measure of 0.91. Our machine learning system achieved a precision of 0.901, recall of 0.899 and F-measure of 0.9 for four-topic classification and a precision of 0.833, recall of 0.823 and F-measure of 0.82 for seven-topic classification. We found in result-containing sentences, the capture of BRCA1/2 mutation information was 75%, but detailed variant information (e.g. variant types) is largely missing. Using cleaned RWD, significant associations were found between BRCA1/2 positive mutation and targeted therapies. Conclusions In conclusion, we demonstrated a framework to generate RWE using RWD from different clinical sources. Rule-based NLP system achieved the best performance for resolving contextual variability when extracting RWD from unstructured clinical notes. Data quality issues such as incompleteness and discrepancies exist thus manual data cleaning is needed before further analysis can be performed. Finally, we were able to use cleaned RWD to evaluate the real-world utility of genetic information to initiate a prescription of targeted therapy.


2012 ◽  
Vol 40 (4) ◽  
pp. 990-996 ◽  
Author(s):  
Ryan Spellecy ◽  
Thomas May

Deception, cheating, and loopholes within the IRB approval process have received significant attention in the past several years. Surveys of clinical researchers indicate common deception ranging from omitting information to outright lying, and controversy surrounding the FDA's decision not to ban “IRB shopping” (the practice of submitting protocols to multiple IRBs until one is found that will approve the protocol) has raised legitimate concerns about the integrity of the IRB process. One author has described a multicenter trial as being withdrawn from consideration at one institution when rejection was imminent, in order to avoid informing other IRBs reviewing the protocol of the study's rejection (a requirement under the federal regulations for emergency research with an exception from informed consent). This practice and IRB shopping seem at odds with the spirit, if not the “letter,” of the regulations. While at first blush these practices seem to cast aspersions on the integrity of clinical researchers, the moral issues raised go deeper than the ethics of cheating.


2021 ◽  
Author(s):  
Meghan Shyama Nagpal ◽  
Antonia Barbaric ◽  
Diana Sherifali ◽  
Plinio P Morita ◽  
Joseph A Cafazzo

BACKGROUND Complications due to Type 2 Diabetes (T2D) can be mitigated through proper self-management which can positively change health behaviours. Technological tools are available to help people living with T2D manage their condition and such tools provide a large repository for patient-generated health data (PGHD). Analytics can provide insights about the ambulatory behaviours of people living with T2D. OBJECTIVE The objective of this review was to investigate analytical insights can be derived through PGHD with respect to ambulatory behaviours of people living with T2D. METHODS A scoping review using the Arksey & O’Malley framework was conducted in which a comprehensive search of the literature was conducted by two reviewers. Three electronic databases (PubMed, IEEE, ACM) were searched using keywords associated with diabetes, behaviours, and analytics. Several rounds of screening using predetermined inclusion and exclusion criteria were conducted and studies were selected. Critical examination took place through a descriptive-analytical narrative method and data extracted from the studies was classified into thematic categories. These categories reflect the findings of this study as per our objective. RESULTS We identified 43 studies that met the inclusion criteria for this review. While 70% of the studies examined PGHD independently, 30% of the studies combined PGHD with other data sources. The majority of these studies used machine learning algorithms to perform their analysis. Themes identified through this review include 1) predicting diabetes / obesity, 2) factors that contribute to diabetes / obesity, 3) insights from social media & online forums, 4) predicting glycemia, 5) improved adherence / outcomes, 6) analysis of sedentary behaviours, 7) deriving behavioural patterns, 8) discovering clinical findings, and 9) developing design principles. CONCLUSIONS The increased volume and availability of PGHD has the potential to derive analytical insights regarding the ambulatory behaviours of people living with T2D. From the literature, we determined that analytics can predict outcomes and identify granular behavioural patterns from PGHD. This review determined the broad range of insights that can be examined through PGHD, that would not be available through other data sources.


Sign in / Sign up

Export Citation Format

Share Document